Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06701669

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients With Acute Respiratory Distress Syndrome (ARDS)

Sponsor: Biomedical Advanced Research and Development Authority

Conditions ARDS ARDS (Acute Respiratory Distress Syndrome) Acute Respiratory Distress Syndrome Acute Respiratory Distress Syndrome (ARDS)

Interventions Cohort B: paridiprubart Cohort B: placebo

Updated 12 times since 2024 Last updated: Feb 16, 2026 Started: Jun 10, 2025 Primary completion: Jul 31, 2028 Completion: Sep 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06701669, this PHASE2 trial focuses on ARDS and ARDS (Acute Respiratory Distress Syndrome) and remains actively recruiting participants. Sponsored by Biomedical Advanced Research and Development Authority, it has been updated 12 times since 2025, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

12 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2

▶ Show 7 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
May 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE2
Mar 2025 — May 2025 [monthly]

Not Yet Recruiting PHASE2
Dec 2024 — Mar 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biomedical Advanced Research and Development Authority
Edesa Biotech Inc.
Genentech, Inc.
InflaRx GmbH
PPD Development, LP

Data source: PPD Development, LP

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Birmingham, United States , Boise, United States , Boston, United States , Bradenton, United States , Burlington, United States , Chapel Hill, United States , Charleston, United States , Cleveland, United States , Denver, United States and 22 more locations